However the benchmark is set, the current focus of MFN policy on Medicaid is inherently less threatening to biopharma companies that the Part B policies of the first Trump Administration. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
